Cover Image
市場調查報告書

黑色素細胞刺激荷爾蒙受體:開發中產品分析

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 374679
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
黑色素細胞刺激荷爾蒙受體:開發中產品分析 Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 61 Pages
簡介

本報告提供以黑色素細胞刺激荷爾蒙受體為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

黑色素細胞刺激荷爾蒙受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Clinuvel Pharmaceuticals Limited
  • Mallinckrodt Plc
  • Palatin Technologies, Inc.
  • Retrophin Inc.
  • SolaranRx, Inc.

藥物簡介

  • afamelanotide
  • AQB-565
  • 腎上腺皮質刺激荷爾蒙
  • cosyntropin
  • CUV-9900
  • PL-8176
  • PL-8177
  • SRX-1177
  • VLRX-001

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1103TDB

Summary:

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 8 respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders and Oncology which include indications Infantile Spasm (West Syndrome), Inflammatory Bowel Disease, Vitiligo, Amyotrophic Lateral Sclerosis, Gouty Arthritis (Gout), Kidney Disease, Metastatic Melanoma, Multiple Sclerosis, Nephrotic Syndrome, Ocular Inflammation, Peritonitis, Porphyria (Erythropoietic Protoporphyri), Psoriatic Arthritis and Uveitis.

The latest report Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
    • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
    • Clinuvel Pharmaceuticals Ltd
    • MallInckrodt Plc
    • Palatin Technologies Inc
    • Retrophin Inc
    • SolaranRx Inc
    • SynAct Pharma AB
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
    • afamelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-1189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQB-565 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUV-9900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-8177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-8331 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-1177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
      • Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
      • Sep 19, 2017: Clinuvel Provides Update on Scenesse FDA Filing
      • Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
      • Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
      • Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
      • Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert
      • Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update
      • Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis
      • Jun 07, 2017: SynAct Pharma announces the start of the clinical phase I study
      • Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims
      • May 25, 2017: Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse
      • May 23, 2017: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse
      • May 02, 2017: NICE England Update on SCENESSE
      • Apr 28, 2017: Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2017
  • Pipeline by MallInckrodt Plc, H2 2017
  • Pipeline by Palatin Technologies Inc, H2 2017
  • Pipeline by Retrophin Inc, H2 2017
  • Pipeline by SolaranRx Inc, H2 2017
  • Pipeline by SynAct Pharma AB, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top